Chi­nese phar­ma pow­er­house Han­soh joins fledg­ling biotechs in the Hong Kong IPO line

More than four months af­ter first open­ing its doors to a big crowd of R&D fo­cused biotechs, the Hong Kong Stock Ex­change has seen a spe­cial guest walk in: A sto­ried com­pa­ny run­ning a prof­itable in­no­v­a­tive and gener­ic drug busi­ness in Chi­na.

Jiang­su Han­soh is fil­ing for an IPO two years af­ter ru­mors of a $3 bil­lion pub­lic de­but first sur­faced. It was found­ed and still run by Hui­juan Zhong, one half of a pow­er cou­ple tow­er­ing over Chi­na’s phar­ma in­dus­try. Her hus­band, Piaoyang Sun, is the head of Jiang­su Hen­grui Med­i­cine, in­ter­na­tion­al­ly known for a PD-1 drug In­cyte paid mil­lions to part­ner with.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER